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Abstract: I n t r o d u c t i o n :  Fecal calprotectin  (FC) rises significantly in in testinal inflam m ation 
accom panied by neutrophil activation — such as Clostridium difficile infection (CDI). The aim of the 
study was to evaluate the benefit of FC testing in assessing the severity of CDI.
M a t e r i a l s  a n d  M e t h o d s :  The study group included 76 patients w ith CDI hospitalized in the 
Jagiellonian University Hospital in Krakow from July 2017 till January 2018. FC levels were measured 
using an EIA (Enzyme Immunoassay). Demographic, clinical inform ation and blood tests were recorded 
using standardized data collection forms. The selection of patients into non-severe and severe groups 
was carried out in accordance w ith the ESCMID criteria (European Society of Clinical Microbiology and 
Infectious Diseases) and some modifications to those criteria were proposed.
R e s u l t s :  The studied population included 76 patients (39 men and 37 women) w ith CDI aged from 24 to 
98 years (mean: 72). M edian calprotectin level was 739 (Q25-Q 75: 612-799 pg/g), characteristic of patients 
w ith colitis. A statistically significant difference in FC concentration in patients w ith severe vs non-severe 
CDI was observed (severe — 770 vs non-severe — 659 pg/g, p = 0.009). FC directly correlated w ith platelets 
level; however, no correlation between FC level and the blood param eters prognostic for CDI (leukocyte, 
neutrophil count, album in, creatinine levels) was found.
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C o n c l u s i o n :  FC level is an indication of ongoing intestinal inflam m ation in CDI patients. FC level 
significantly correlated w ith CDI severity, which dem onstrates tha t FC could serve as a predictive marker 
for assessing CDI severity.
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Introduction
Clostridium difficile (C. difficile) is a Gram-positive, anaerobic, spore-forming 
bacillus responsible for one of the most notable healthcare-associated infections 
of the last two decades, one with a significant morbidity and mortality. The most 
im portant risk factors for C. difficile infection (CDI) development are antibiotic 
exposure, older age, and hospitalization. The main protective barrier against CDI is 
the normal intestinal microflora. Destruction of that barrier as a result of antibiotic 
use facilitates the colonization of the intestine by C. difficile and the progress of 
CDI symptoms. The pathogen is not invasive, and its virulence is mostly a result 
of C. difficile enzyme production, such as collagenase, hyaluronidase, chondroitin- 
sulfatase, and toxins (toxin A and B), which damage the epithelial cell cytoskeleton, 
stimulate neutrophil adhesion and local inflammation [1-3]. The clinical picture 
of CDI is very heterogeneous, and ranges from the asymptomatic carrier state to 
life-threatening colitis. Typical symptoms include diarrhea, abdominal pain, fever, 
nausea and vomiting, weakness, and loss of appetite. The most severe complications 
are toxic megacolon, colon perforation, intestinal paralysis, kidney failure, systemic 
inflammatory response syndrome, septicemia and death [4-6]. Currently, several 
methods of fast diagnosis of CDI are available. The best way to optimize the diagnosis 
is to combine two tests in an algorithm. The first test should be one with high negative 
predictive value (either GDH EIA or NAAT). The second test should be a test with 
a high positive predictive value (toxin A/B EIAs) [7].
Calprotecin is a 36 kDa calcium- and zinc- binding protein, produced mostly by 
neutrophils and to some extent by monocytes/macrophages. The protein complex 
belongs to the S100 family and it is composed of two hydrophobic non-covalently 
linked S100A8/A9 regions [8, 9].
Calprotectin is stored in neutrophil granules, constituting about 5% of proteins, 
whereas in monocytes and macrophages it can comprise up to 60% of cytosolic 
proteins [8]. It has antimicrobial properties — bacteriostatic and fungistatic, due to 
the competitive binding of manganese and zinc [9, 10]. Calprotectin has been shown 
to exhibit antimicrobial activity against Escherichia coli, Klebsiella sp., Staphylococcus 
aureus [8]. The fecal calprotectin (FC) level rises in intestinal inflammation, as 
neutrophils are activated. Crucially, it is thought that unlike other inflammation
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markers such as erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP), 
inflammatory reactions other than intestinal do not cause a significant increase in 
calprotectin level [9]. Its fecal excretion is highly correlated to that of 111-indium- 
radiolabeled leukocyte scanning, the gold standard for m easurem ent of severity 
of intestinal inflam m ation [11]. Furtherm ore, the m easurem ent is relatively 
straightforward, requiring approximately 5 grams of fecal matter. A noteworthy 
characteristic of calprotectin itself is its stability, reaching up to 7 days in room 
tem perature [12]. However, one study indicates that FC concentration in stool 
samples stored in room  temperature starts to decrease 3 days after collection [13]. 
Therefore, before assay, the sample can be safely stored in low temperatures, a week 
m inim um  in 2-8°C and in -2 0  C and below a m inim um  of 4 m onths without 
a drop in FC detectability [14]. An exact cut-off has not been defined; however, 
numerous studies suggest that concentrations of <50 pg/g would be seen as normal; 
50-100 pg/g represent a weakly positive test; >100 pg/g indicate a positive result [12]. 
As m entioned above, an increase in FC is an indication of ongoing intestinal 
inflammation — in healthy people FC levels are lower and not influenced by lifestyle 
factors. FC level in healthy people is approximately 50 pg/g for adults and children 
older than 4 years [12].
Materials and Methods
The study group included 76 patients with CDI hospitalized from 1 July 2017 till 
31 January 2018 at the Jagiellonian University Hospital in Krakow, aged from 24 to 
98 years (mean: 72 years; 39 men and 37 women). The diagnosis of CDI was based 
on patient history, epidemiological data, physical examination, and laboratory tests 
according to the ESCMID (European Society of Clinical Microbiology and Infectious 
Diseases) guidelines [15]. Outcomes included severe CDI (intensive care unit 
admission, colectomy, death attributable to CDI within 30 days of diagnosis), and 
90 days all-cause mortality. CDI was diagnosed in patients experiencing diarrhea, 
defined as the passage of 3 or more unformed stools in 24 hours. The infection was 
then confirmed by the detection of the C. difficile antigen and toxins in feces using 
the C. difficile Quick Check Complete test kit (TechLab Inc., Blacksburg, USA). When 
the test came back positive for the antigen but negative for the toxin, the test for the 
C. difficile toxin was repeated with the ELISA C. difficile toxin A/B II test kit (TechLab 
Inc., Blacksburg, USA). The study was conducted in accordance with the Declaration 
of Helsinki (1975), and approved by the Jagiellonian University Ethics Committee 
[protocol number: 1072.6120.51.2018]. Exclusion criteria included the presence of 
other acute or chronic inflammatory diseases of the digestive tract.
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Patient qualification into the non-severe and severe groups according
to the ESCMID criteria
Patient qualification into the non-severe and severe groups was performed based 
on ESCMID criteria [15]. Severe CDI was defined as an episode of this infection 
with one or more specific signs and symptoms of severe colitis or a complicated 
course of disease, with significant systemic toxin effects and shock, resulting in 
need for ICU (intensive care unit) admission, colectomy or death. One or more of 
the following unfavorable prognostic factors can be present during the course of the 
disease: marked leukocytosis (leucocyte count >15 x 109/L), decreased blood albumin 
(<30 g/L), kidney impairment (rise in serum creatinine level >133 pM or >1.5 times 
the premorbid level or glomerular infiltration rate (GFR) reduced by 25% from 
baseline). In adherence to those criteria, 50 people were categorized as severe and 
26 as non-severe.
Modification proposal of the ESCMID criteria of patient classification 
into non-severe and severe groups
Having analyzed the ESCMID criteria, we have proposed an adjusted version of 
the distribution criteria. The presence of clinical events such as: ICU admission, 
colectomy, death indisputably allow to qualify patient to the “severe” CDI group. 
However, these factors often occur at a later stage of the disease. Significant 
disturbances in the 3 known factors of poor CDI prognosis (hypoalbuminemia, WBC 
increase, creatinine and GFR changes) are extremely important, because they often 
allow to predict a severe course of CDI. On the other hand, deviations in the above 
parameters appear relatively frequently, hence the qualification to the “severe” group 
in the presence of two rather than one impaired parameter (hypoalbuminemia, WBC 
increase, creatinine and GFR changes) in our opinion is much more accurate in 
predicting the severity of CDI.
Therefore, we have defined the modified criteria of CDI severity as follows:
Severe CDI was defined as an episode of this infection with one or more 
specific signs and symptoms of severe colitis or a complicated course of disease, 
with significant systemic toxin effects and shock, resulting in either: need for ICU 
admission, colectomy or death. Two or more of the following unfavorable prognostic 
factors can be present during the course of the disease: marked leukocytosis (leucocyte 
count >15 x 109/L), decreased blood albumin (<30 g/L), kidney impairment (rise in 
serum creatinine level >133 pM or >1.5 times the premorbid level or glomerular 
infiltration rate (GFR) reduced by 25% from baseline). In adherence to those criteria, 
31 people were categorized as severe and 45 as non-severe. Using this classification, 
FC was compared in both groups.
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Sample collection and  data gathering
All samples came from stool left over in the main laboratory. The samples were stored 
in a frozen (-80°C) state until the calprotectin test was performed. Demographic data 
(age, sex) and clinical data (outcome of CDI infection, intensive care unit admission, 
colectomy, death, and blood tests information) were recorded using standardized data 
collection forms. Blood tests included complete blood count (CBC), creatinine, GFR, 
albumin and CRP level.
Fecal calprotectin  analysis
The stool samples were tested with Ridascreen" Calprotectin immunoassay 
marketed by R-Biopharm AG in accordance with the supplied instructions. Briefly: 
5 ml of extraction buffer was added to every 100 mg sample and homogenized 
for approximately 30 seconds (depending on consistency), then centrifuged for 
10 minutes with the velocity of 3000 G. The obtained supernatant was diluted 50-fold 
and in 100 pl portions transferred to reaction plates. Several other wells contained 
100 pl of negative control in 100 pl (5 standards), 100 pl of positive control and 
a 100 pl of weak positive control. Every sample was incubated (covered) for 60 
minutes in room temperature. After incubation, the samples were rinsed 5 times 
with a rinse buffer, a conjugate was added and the mixture was again incubated for 
60 mins in room temperature. Subsequently, every reaction well was rinsed 5 times 
with a rinse buffer, the substrate was added and the covered plate was incubated in 
a darkroom in room temperature for 15 minutes. After the appointed time period 
the reaction was halted with a STOP reactant. Photometric analysis was performed 
with the wavelength of 450 nm  and reference wavelength of 620 nm  in a BIO-RAD 
PR 3100 spectrophotometer. Calprotectin concentrations were recorded on a standard 
curve, drawn according to the manufacturer’s instructions, for each sample series.
Statistics
All data is presented as medians and lower (Q25), upper (Q75) quartiles. Normal 
distribution of variables was checked using the Shapiro-W ilk test. Differences 
between study groups were determined using the M ann-W hitney U-test if normality 
was not observed. Correlation between selected variables was evaluated using 
a Pearson correlation coefficient; in the absence of normal distribution, Spearman’s 
rank correlation was used. Calculations were performed using StatSoft, Inc. (2011), 
STATISTICA, version 13 statistical package software licensed for the Jagiellonian 
University, and statistical significance was defined as p <0.05.
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Results
The study consisted of 76 patients with C. difficile infection (39 women, 37 men) 
hospitalized from July 2017 till January 2018 in the mean age of 72 (ranged from 
24 to 98 years). In the analyzed group there were 64 patients with a first and 12 with 
a recurring episode of CDI. Patients with a recurring episode of CDI were analyzed 
only once. The results of biochemical parameter analysis have shown that patients 
with CDI suffered from very intensive systemic inflammatory reaction, which was 
manifested by the increase in inflammatory markers. The median level of calprotectin 
was typical for people with colitis (Table 1). The table does not include the results of 
a patient with leukemia, after chemotherapy, the results of which were significantly 
influenced by primary disease and chemotherapy, as well as a patient who died shortly 
after beginning of diarrhea, hence it was possible to take feces for C. difficile diagnosis, 
but no blood was collected before death. Approximately 50% of patients did not have 
white blood cell smears, 13% have not had albumin and CRP levels tested. In almost 
all cases, the levels of albumin and CRP were not performed in people whose diarrhea 
was characterized by a very mild and short-lasting course of CDI.
Table 1. Results of the assessed parameters in the study groups.
Param eter
Patients w ith CDI
n m edian (Q25-Q 75)
WBC (x103/pl) 74 8.6 (6.8-15.6)
neutrophils (x103/pl) 35 4.9 (3.8-12.3)
RBC (x106/pl) 74 3.8 (3.3-4.2)
Haemoglobin (g/dl) 74 10.6 (9.4-11.7)
Haem atocrit (%) 74 31.9 (29.2-35.6)
platelets (x103/pl) 74 246 (181-324)
creatinine (pmol/l) 75 91 (68-141)
GFR (m l/min/1.73m2) 75 69 (48-91)
Album in (g/l) 66 28.9 (23.5-33)
CRP (mg/l) 66 61 (17-131)
Fecal calprotectin (pg/g) 76 739 (612-799)
CDI — Clostridium difficile infection; CRP — C-reactive protein; GFR — glomerular filtration rate; RBC — red 
blood cells; Q25 — lower quartile; Q75 — upper quartile; WBC — white blood cells
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Non-severe vs severe CDI — according to ESCMID
Subsequently, a statistical comparison of assessed parameters was performed, dividing 
the patients into the non-severe and severe subgroups of CDI. A statistically higher 
FC concentration was observed in the severe vs non-severe CDI (severe — 770 
vs non-severe — 659 pg/g, p = 0.009). Furthermore, patients with severe CDI 
exhibited significantly higher values of WBC, neutrophils, creatinine, CRP and lower 
GFR, albumin compared to the non-severe group (Table 2).
Table 2. Results of the assessed param eters in the study groups divided into the non-severe and severe 
subgroups.
Param eter
CDI non-severe CDI severe
P
n m edian (Q25-Q 75) n m edian (Q25-Q 75)
WBC (x103/pl) 26 7.3 (6.3-8.0) 48 13.2 (7.5-18.8) p <0.001
neutrophils (x103/pl) 13 4.1 (3.4-4.8) 22 10.4 (4.8-18.8) 0.008
RBC (x106/pl) 26 3.8 (3.4-4.2) 48 3.8 (3.2-4.2) 0.42
Haemoglobin (g/dl) 26 10.7 (10.2-11.7) 48 10.3 (8.9-11.8) 0.14
Haem atocrit (%) 26 33 (31-35) 48 31.8 (28-36) 0.12
platelets (x103/pl) 26 245 (180-311) 48 247 (183-330) 0.78
creatinine (pmol/l) 26 75 (60-86) 49 120 (80-169) 0.001
GFR (m l/min/1.73m2) 26 90 (72-93) 49 54 (35-78) <0.001
A lbum in (g/l) 22 34 (32-36) 44 25 (22-28.9) <0.001
CRP (mg/l) 21 15 (6-58) 45 80 (40-158) <0.001
Fecal calprotectin (pg/g) 26 659 (369-775) 50 770 (689-802) 0.009
CDI — Clostridium difficile infection; CRP — C-reactive protein; GFR — glomerular filtration rate; RBC — red 
blood cells; Q25 — lower quartile; Q75 — upper quartile; WBC — white blood cells
Comparison of FC level using proposed modifications of ESCMID criteria
Table 3. Comparison of FC level using proposed modifications of ESCMID criteria.
Param eter
CDI non-severe CDI severe
P
n m edian (Q25-Q 75) n m edian (Q25-Q 75)
Faecal calprotectin (pg/g) 45 661 (581-789) 31 780 (714-810) 0.001
CDI — Clostridium difficile infection; CRP — C-reactive protein; Q25 — lower quartile; Q75 — upper quartile
A statistically higher FC concentration was observed in the severe vs non-severe 
CDI (severe — 780 vs non-severe — 661 pg/g, p = 0.001).
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Deaths
The evaluation of patients with CDI showed 20 deaths among the 76 people, 13 of 
which originated directly from CDI — sequentially or clinically. In the remaining 
7 cases, the CDI had been successfully treated with death attributed to different 
mechanisms. The mortality rate was 17% (n = 13/76) where death was directly 
attributed to CDI and 26% (n = 20/76) where all deaths were included. Where CDI 
was the contributing factor, the time from diagnosis to death averaged 10 days 
(1-22 days). In the remaining 7 cases that timeframe was 36 days (21-45 days). There 
was no significant difference in FC level between group with no CDI-related deaths 
and those with CDI-related deaths. However, significantly higher values of WBC, 
creatinine, and CRP and a lower GFR and albumin were observed in people who had 
died than in those who had survived CDI (Table 4).
Table 4. Results of the assessed parameters in the study groups divided into patients w ith no CDI-related 
deaths (n = 63) and CDI-related deaths (n = 13) subgroups.
Param eter




n m edian (Q25-Q 75) n m edian (Q25-Q 75)
WBC (x103/pl) 63 8.04 (6.5-14.3) 11 13.7 (9.3-26.9) 0.03
neutrophil (x103/pl) 29 4.8 (3.6-10.6) 6 14.5 (4.9-29) 0.07
RBC (x106/pl) 63 3.8 (3.3-4.1) 11 3.9 (3.1-5.4) 0.52
Haemoglobin (g/dl) 63 10.5 (9.5-11.7) 11 11.1 (8.6-13.7) 0.95
H aematocrit (%) 63 32.3 (30-35) 11 32 (27.4-40.8) 0.92
platelets (x103/pl) 63 247 (180-324) 11 246 (199-404) 0.73
creatinine (pmol/l) 63 85 (60-130) 12 163 (118-350) 0.004
GFR (m l/min/1.73m2) 63 74 (51-92) 12 37 (14-54) 0.002
A lbum in (g/l) 57 29 (25-33) 9 24 (19.7-26.1) 0.009
CRP (mg/l) 55 51 (11.9-104) 11 198 (74-304) <0.001
Fecal calprotectin (pg/g) 63 727 (607-798) 13 772 (693-800) 0.27
CDI — Clostridium difficile infection; CRP — C-reactive protein; GFR — glomerular filtration rate; RBC — red 
blood cells; Q25 — lower quartile; Q75 — upper quartile; WBC — white blood cells
The last test was designed to determine whether the calprotectin concentration 
correlates with the assessed blood parameters and we found only one such correlation 
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Table 5. Correlations between measured parameters in patients with CDI.
Param eters compared r P
WBC vs CRP 0.34 0.005
WBC vs album in -0.42 <0.001
WBC vs platelets 0.26 0.02
N eutrophil vs album in -0.48 0.005
CRP vs album in -0.40 0.004
CRP vs haematocrit -0.25 0.047
album in vs haemoglobin 0.38 0.001
album in vs haem atocrit 0.37 0.002
Fecal calprotectin vs platelets 0.28 0.02
CRP — C-reactive protein; WBC — white blood cells
Discussion
Numerous studies have shown that the concentration of calprotectin in the stool 
correlates with the intestinal inflammation. So far, this test has found use primarily 
in diagnosing and monitoring the course of IBD [16-18]. Van Rheenen et al. in 
their study including 670 adults with suspicion of IBD found that the sensitivity 
and specificity of calprotectin was 0.93 and 0.96 [19]. Von Roon et al. performed 
a meta-analysis using data from 9 studies comparing FC in IBD subjects in respect 
to IBS (irritable bowel syndrome) subjects or healthy controls. They showed that the 
overall sensitivity and specificity of FC equaled 95% and 91% respectively for the 
identification of patients with IBD. Moreover, the level of FC was higher by 219.2 pg/g 
in patients with IBD compared with healthy controls. They also demonstrated that 
as a cut-off, the value of 100 pg/g functions better than 50 pg/g in the diagnosis of 
IBD [20]. The efficiency of calprotectin in identifying IBD is markedly higher than the 
widely used CPR, ESR, mti-Saccharomyces cerevisiae antibody (ASCA) or perinuclear 
antineutrophil cytoplasmic antibody (ANCA) [18].
Neutrophil infiltration is one of the basic drivers of the development of symptoms 
of CDI and it is known that neutrophils play a major role in the pathogenesis of the 
disease [21]. Toxins produced by C. difficile damage the enterocytes, which leads to 
degradation of the cytoskeleton and an increase in the epithelial barrier permeability, 
resulting in local inflammation, mast cell degranulation, epithelial cell death, and 
neutrophil recruitm ent [22]. The higher inflammation intensity in CDI, the bigger 
the increase in neutrophil count [21]. Considering the neutrophils’ role in CDI 
pathogenesis, it would seem logical to assume that in this disease a calprotectin test 
could similarly prove its clinical value. Results of the studies conducted so far have
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been inconclusive. Kim et al. demonstrated that FC significantly correlated with CDI 
severity and also was able to discriminate between severe CDI, mild CDI, and healthy 
controls. FC concentrations were higher (p <0.001) in the 30 severe CDI patients 
(median, 1.391 pg/g) than in the 50 mild CDI patients (median, 188.2 pg/g), and both 
were higher than those of the healthy controls (median, 35.6 pg/g) [23]. Rao et al. have 
shown that high FC (>2000 ug/g) was associated with adverse outcomes (complicated/ 
recurrent) CDI in older adults, however, in their study the number of patients with 
these outcomes was relatively small (5 patients with complicated and 8 with recurrent 
CDI). Moreover, well known and im portant for severe CDI parameters like age, 
comorbidities, WBC did not correspond to CDI severity in their study — the authors 
seem to think that this could indicate that calprotectin, which was associated with 
adverse outcomes despite the small sample size, is a stronger predictor than clinical 
variables. This, however, is a bold theory and only an investigation on a larger scale 
would do it justice [24]. ^ a t  argument is furtherly weakened by Swale et al. who have 
observed no statistically significant difference in FC comparing patients with severe 
CDI vs. non-severe CDI, as well as seen no correlation with all-cause mortality [25]. 
Peretz et al. in a small study (29 patients) assessed FC correlation with virulent 
ribotype 027 strain infection and clinical and laboratory measures of disease severity. 
They found higher FC levels in patients with C. difficile ribotype 027 (p <0.0005) and 
a positive correlation between FC and WBC (p = 0.007). No correlation was found 
regarding CDI severity, age, sex, functional status, community versus hospital acquired 
CDI, antibiotic susceptibility, fever, and creatinine levels [26]. In a Swale et al. study 
with a larger population sample (164 patients) there was no correlation between FC 
levels and ribotype 027 [25]. Swale et al. found significant differences between CDI 
and controls (684 vs 67 mg/kg), in this study control patients were individuals with 
evidence of antibiotic-associated diarrhea (AAD), but negative toxin ELISA test and 
microbiological cultures, with no past history of CDI. No significant differences for 
FC comparing severe vs non-severe CDI was found. ^ e r e  was also no correlation 
with 90-day recurrence, prolonged CDI symptoms, positive culture results [25]. In 
another study Wultanska et al. also found that there were no statistically significant 
differences in the concentration of calprotectin between patients infected with RT027 
and different PCR ribotypes than RT027 [27].
In our study, we have demonstrated a clear-cut (p = 0.009), statistically signifi­
cant difference between patients with severe and non-severe CDI using the ESCMID 
criteria. One plausible explanation, partial at least, for the divergence in study results 
could be the lack of uniform criteria stratifying the non-severe and severe. ^e re fo re  
we have proposed more accurate, modified criteria and statistically significant differ­
ence of FC level between patients with severe and non-severe CDI using modified 
criteria was also confirmed (p = 0.001).
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Presently, the antibiotics in CDI management are vancomycin, fidaxomicin and 
metronidazol. The drug and dose of choice depend on CDI severity — in the most 
severe fulminant form vancomycin 500 mg orally 4 times a day and metronidazole 
500 mg IV 3 times a day is used [4]. It is param ount to correctly categorize the 
patients into risk strata for CDI severity early on, as timely and suitable treatment 
increases the chance of recovery and survival rate. Therefore, the search for new 
markers of severe CDI could prove extremely beneficial. That, coupled with the 
FC test being inexpensive, easy and FC itself stable in room  temperature makes it 
a promising candidate [14]. Despite having demonstrated a significant increase in FC 
in patients with severe CDI, a similar correlation with deaths in our study has not 
been observed. This could be attributed to the relatively small group of patients who 
died — only 13. Therefore, it is vital to continue with a larger population sample, 
performing a detailed clinical analysis — patients with CDI usually suffer from 
a number of comorbidities, often fatal — e.g. terminal cancer. The overall-mortality 
in our group was high, reaching 26%. It is worth noting that after a clinical analysis, 
35% of overall deaths (7 out of 20) were deemed unrelated to CDI.
We have found that FC correlated with platelets, but no other correlation was 
found between FC and the assessed blood param eters. However, a statistically 
significant and directly proportional relation was found between the WBC count 
and CRP and also platelets what reflects the nature of CDI as a disease with a strong 
inflammatory component. Some interesting results have been obtained pertaining to 
CRP and albumin relation to RBC parameters — as CDI is not known to directly 
cause anemia, which can be explained by numerous comorbidities of varying severity. 
The comorbidity analysis was not the aim of our study; however, the large percentage 
of all-mortality (26%) and particularly the percentage of CDI-unrelated deaths (35%, 
7 out of 20 deaths) may confirm this hypothesis.
Conclusions
FC is an indication of ongoing intestinal inflammation in CDI patients. The FC levels 
significantly correlated with CDI severity, which shows it could prospectively serve as 
a predictive marker for assessing CDI severity. The ongoing search for CDI severity 
markers is particularly vital, enabling fast and optimal treatment approach, which is 





64 M irosław Dróżdż, Grażyna Biesiada, et al.
References
1. Leffler D.A., Lamont J.T.: Clostridium difficile infection. N Engl J Med. 2015; 372: 1539-1548.
2. Vaishnavi C.: Clinical spectrum & pathogenesis of Clostridium difficile associated diseases. Indian J 
Med Res. 2010; 131: 487-499.
3. Moore S.C.: Clostridium difficile: more challenging than ever. Crit Care Nurs Clin North Am. 2018; 
30: 41-53.
4. McDonald L.C., Gerding D.N., Johnson S., et al.: Clinical practice guidelines for Clostridium difficile 
infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) 
and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018; 66: e1-e48.
5. Surawicz C.M., Brandt L.J., Binion D.G., et al.: Guidelines for diagnosis, treatment, and prevention of 
Clostridium difficile infections. Am J Gastroenterol. 2013; 108: 478-498.
6. Bartlett J.G.: Clostridium difficile infection. Infect Dis Clin N Am. 2017; 31: 489-495.
7. Crobach M.J.T., Planche T., Eckert C., et al.: European Society of Clinical M icrobiology and 
Infectious Diseases: update of the diagnostic guidance docum ent for Clostridium difficile infection. 
Clin Microbiol Infect. 2016; 22: S63-S81.
8. Sum m erton C.B., Longlands M.G., Wiener K., Shreeve D.R.: Faecal calprotectin: a m arker of 
inflammation throughout the intestinal tract. Eur J Gastroenterol Hepatol. 2002; 14: 841-845.
9. Montalto M., Gallo A., Santoro L., D ’Onofrio F., Landolfi R., Gasbarrini A.: Role of fecal calprotectin 
in gastrointestinal disorders. Eur Rev Med Pharmacol Sci. 2013; 17: 1569-1582.
10. Manceau H., Chicha-Cattoir V., Puy H., Peoc’h K.: Fecal calprotectin in inflammatory bowel diseases: 
update and perspectives. Clin Chem Lab Med. 2017; 55: 474-483.
11. Roseth A.G., Schmidt P.N., Fagerhol M.K.: Correlation between faecal excretion of indium-111- 
labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory 
bowel disease. Scand J Gastroenterol. 1999; 34: 50-54.
12. Gisbert J.P., McNicholl A.G.: Questions and answers on the role of faecal calprotectin as a biological 
m arker in inflammatory bowel disease. Dig Liver Dis. 2009; 41: 56-66.
13. Lasson A., Stotzer P.O., Ohman L., Isaksson S., Sapnara M., Strid H.: The intra-individual variability
of faecal calprotectin: a prospective study in patients with active ulcerative colitis. J Crohns Colitis. 
2015; 9: 26-32.
14. Hessels J., Douw G., Yildirim D.D., Meerman G., van Herwaarden M.A., van den Bergh F.A.:
Evaluation of prevent ID and quantum blue rapid tests for fecal calprotectin. Clin Chem Lab Med.
2012; 50: 1079-1082.
15. Debast S.B., Bauer M.P., Kuijper E.J.: ESCMID European Society of Clinical M icrobiology and 
Infectious Diseases update of the treatm ent guidance docum ent for Clostridium difficile infection. 
Clin Microbiol Infect. 2014; 20: 1-26.
16. Angriman I., Scarpa M., D ’Inca R.: Enzymes in feces: useful markers of chronic inflammatory bowel 
disease. Clin Chim Acta. 2007; 381: 63-68.
17. Vermeire S., van Assche G., Rutheerts P: Laboratory markers in IBD: useful, magic, or unnecessary 
toys? Gut 2006; 55: 426-431.
18. Sutherland A.D., Gearry R.B., Frizelle F.A.: Review of fecal biom arkers in inflam m atory bowel 
disease. Dis Colon Rectum. 2008; 51: 1283-1291.
19. van Rheenen P.F., van de Vijver E., Fidler V.: Faecal calprotectin for screening of patients with 
suspected inflammatory bowel disease: diagnostic meta-analysis. Br Med J. 2010; 341: c3369.
20. von Roon A.C., Karamountzos L., Purkayastha S.: Diagnostic precision of fecal calprotectin for 
inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol. 2007; 102: 803-813.
21. Czepiel J., Biesiada G., Brzozowski T., et al.: The role of local and systemic cytokines in patients 
infected with Clostridium difficile. J Physiol Pharmacol. 2014; 65: 695-703.
The level o f feca l calprotectin significantly correlates with C lostridium  difficile infection severity 65
----------------------------------------  www.czasopisma.pan.pl
c3*o www.journals.pan.pl ----------------------------------------------------
22. Penichea A.G., Savidge T.C., Dann S.M.: Recent insights into Clostridium difficile pathogenesis. Curr 
Opin Infect Dis. 2013; 26: 447-453.
23. Kim J., Kim H., Oh H.J.: Fecal calprotectin level reflects the severity of Clostridium difficile Infection. 
Ann Lab Med. 2017; 37: 53-57.
24. Rao K., Santhosh K., Mogle J.A., Higgins P.D., Young V.B.: Elevated fecal calprotectin associates with 
adverse outcomes from Clostridium difficile infection in older adults. Infect Dis (Lond). 2016; 48: 
663-669.
25. Swale A., Miyajima F., Roberts P., et al.: Calprotectin and lactoferrin faecal levels in patients with 
Clostridium difficile infection (CDI): a prospective cohort study. PLoS One. 2014; 9: e106118.
26. Peretz A., Tkhawkho L., Pastukh N., Brodsky D., Halevi C.N., Nitzan O.: Correlation between fecal 
calprotectin levels, disease severity and the hypervirulent ribotype 027 strain in patients with 
Clostridium difficile infection. Infect Dis. 2016; 16: 309.
27. Wultanska D., Obuch-Woszczatynski P., Piotrowski M., Pituch H.: Assessment of fecal calprotectin 
concentration in samples from patients with Clostridium difficile infection. Med Dosw Mikrobiol. 
2018; 70: 159-165.
